Sugi Predict

Sugi Predict / Targets / SLC12A5

SLC12A5

Solute carrier family 12 member 5 · Q9H2X9 · SLC12A5 on Sugi Atlas →

2,449 patent compounds predicted against SLC12A5, 1,785 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1916714 SCHEMBL1916714 0.37 5/20
SCHEMBL1916720 SCHEMBL1916720 0.37 5/20
SCHEMBL1914986 SCHEMBL1914986 0.36 5/20
SCHEMBL1914991 SCHEMBL1914991 0.36 5/20
SCHEMBL1916038 SCHEMBL1916038 0.36 5/20
SCHEMBL1916040 SCHEMBL1916040 0.36 5/20
SCHEMBL1916935 SCHEMBL1916935 0.35 5/20
SCHEMBL1916938 SCHEMBL1916938 0.35 5/20
SCHEMBL1916197 SCHEMBL1916197 0.34 5/20
SCHEMBL1916203 SCHEMBL1916203 0.34 5/20
SCHEMBL1915453 SCHEMBL1915453 0.34 5/20
SCHEMBL1915459 SCHEMBL1915459 0.34 5/20
SCHEMBL2051654 SCHEMBL2051654 0.34 5/20
SCHEMBL2399185 SCHEMBL2399185 0.34 5/20
SCHEMBL1915893 SCHEMBL1915893 0.34 4/20
SCHEMBL1915897 SCHEMBL1915897 0.34 4/20
SCHEMBL1916941 SCHEMBL1916941 0.34 4/20
SCHEMBL1917312 SCHEMBL1917312 0.34 4/20
SCHEMBL1917321 SCHEMBL1917321 0.34 4/20
SCHEMBL2397947 SCHEMBL2397947 0.34 4/20

Clinical trials — most relevant to SLC12A5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Age on the Renal Clearance of Adefovir PHASE4WITHDRAWN
Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorder PHASE1/PHASE2NOT_YET_RECRUITING
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) PHASE2COMPLETED
CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops PHASE2UNKNOWN
Effect of, OAT3, on the Renal Secretion of Cefotaxime PHASE1COMPLETED
THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC PHASE1COMPLETED
Genetic Variation in Organic Cation Transport 1 (OCT1) and Its Significance for Morphine Pharmacokinetics PHASE1COMPLETED
Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors PHASE1RECRUITING
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters EARLY_PHASE1COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer EARLY_PHASE1UNKNOWN
SLC13A5 Deficiency Natural History Study - Remote Only nanENROLLING_BY_INVITATION
Oxalate and Citrate in Humans - Response to Citrate nanRECRUITING
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
Bile Acid Effects in Fetal Arrhythmia Study nanUNKNOWN
SLC13A5 Deficiency Natural History Study - United States Only nanENROLLING_BY_INVITATION
Genetically Guided Statin Therapy nanCOMPLETED
Impact of Genetics on Metformin Pharmacokinetics nanCOMPLETED
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides nanCOMPLETED
Genetic Variants and Iron Absorption nanCOMPLETED
Oxalate and Citrate nanRECRUITING
Effect of SLC01B1 (rs4149956) Polymorphism on the Efficacy and Tolerability of Atorvastatin in Pakistani Population nanCOMPLETED
Gyrate Atrophy Ocular and Systemic Study nanACTIVE_NOT_RECRUITING
ADPKD Alterations in Hepatic Transporter Function nanCOMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs nanCOMPLETED
Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias nanCOMPLETED
Autonomic Function in Patients With COPD nanCOMPLETED
Regulation of Human Intestinal Bile Acid Transport in Health and Disease nanCOMPLETED
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals nanENROLLING_BY_INVITATION
Renal Transporters After Renal Transplantation nanUNKNOWN
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC12A5 binder may also engage these)

ProteinNameSimilarity
Q9UHW9 — 1.000 Q9UHW9 →
Q9JIS8 — 1.000 Q9JIS8 →
Q63633 — 1.000 Q63633 →
Q91V14 — 0.999 Q91V14 →
Q924N4 — 0.999 Q924N4 →
Q9Y666 — 0.998 Q9Y666 →
Q7YRU6 — 0.998 Q7YRU6 →
Q5RK27 — 0.997 Q5RK27 →
Q9WVL3 — 0.997 Q9WVL3 →
Q63632 — 0.997 Q63632 →
Q9UP95 — 0.997 Q9UP95 →
Q2UVJ5 — 0.996 Q2UVJ5 →
Q28677 — 0.992 Q28677 →
Q6Z0E2 — 0.990 Q6Z0E2 →
Q09573 — 0.989 Q09573 →
Q657W3 — 0.989 Q657W3 →
Q25479 — 0.986 Q25479 →
Q61609 — 0.986 Q61609 →
Q5XHF9 — 0.985 Q5XHF9 →
Q8TBB6 — 0.984 Q8TBB6 →
Q3E7D0 — 0.984 Q3E7D0 →
P38329 — 0.984 P38329 →
SLC6A19 Sodium-dependent neutral amino acid transporter B(0)AT1 0.984 landscape →
Q3E954 — 0.983 Q3E954 →
B4JMC1 — 0.983 B4JMC1 →
Q920R6 — 0.983 Q920R6 →
Q62687 — 0.983 Q62687 →
Q6U841 — 0.982 Q6U841 →
SLC6A9 Sodium- and chloride-dependent glycine transporter 1 0.982 landscape →
Q53P98 — 0.982 Q53P98 →